Current and Potential Biologic Drugs for the Treatment of Chronic Urticaria.
Angioedema
Biologics
Chronic urticaria
Omalizumab
Journal
Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
5
10
2021
Statut:
ppublish
Résumé
This article reviews biologic treatments that are currently applied for the treatment of severe chronic urticaria. Monoclonal anti-immunoglobulin E (omalizumab) is effective and safe in many patients, but accessibility and cost constitute barriers to its wider use. Questions on the optimal duration of the treatment and possible symptom recurrences after discontinuing the drug are still raised. A discussion is presented about several other biologics currently under investigation with potential to be incorporated in the near future in patients with severe chronic urticaria.
Identifiants
pubmed: 33012323
pii: S0889-8561(20)30040-0
doi: 10.1016/j.iac.2020.06.005
pii:
doi:
Substances chimiques
Biological Products
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
609-623Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest M. Sánchez-Borges has received honoraria for lectures from Novartis. S.G. Díaz, J.A. Ortega-Martell, M.I. Rojo, and I.J. Ansotegui have nothing to disclose.